Leading the way to safer medication
 Crosscheck  Recommender

Canacinumab

Description

Canakinumab is a human monoclonal anti-human interleukin-1 beta (IL-1 beta) antibody of the IgG1/κ isotype. Canakinumab binds with high affinity specifically to human IL-1 beta and neutralises the biological activity of human IL-1 beta by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and the production of inflammatory mediators.

ATC Classification

Code
Title
Category
L04AC08
Canacinumab
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors

Trade names

Trade name
Countries

Austria Canada Cyprus France Netherlands

Product Monographs

Monograph
Type
Country
ILARIS Powder for solution for injection
MPI, EU: SmPC